Like most biologic agents, the manufacturing of belatacept is difficult, timeconsuming and expensive. To this end, the manufacturer of belatacept has been transitioning to a more efficient and higher yielding manufacturing process.
Unfortunately, this transition has experienced a significant delay, but the reasons for this setback are unknown. It is important to note that the FDA mandates that when a change is made in drug manufacturing, prior to its approval for distribution, the manufacturer must validate any changes in identity, strength, quality, purity, Overall, it has been well documented that both the United States and Europe have experienced an increased frequency of drug shortages, which have resulted in difficulties for patients, practitioners, health care facilities, and even federal regulators.(5-7) There are many factors that contribute to drug shortages, including reduced availability of raw materials, manufacturing difficulties, regulatory issues, and manufacturer marketing decisions, to name a few. Importantly, tendering, as a method of cost-containment, has also been identified as a cause of drug shortages.
Tendering is a process in which payers (ie, private or government insurance), negotiates the lowest price for a medication with multiple producers. The supplier offers the lowest price has their medications available on the payers' insurance plans for the duration of the contract. The low drug prices resulting from tendering can reduce the number of suppliers, making drugs more susceptible to shortages.
A C C E P T E D
Production of pharmaceuticals is becoming more and more concentrated, to increase efficiency. Thus, there may be only 1 active producer worldwide. If this sole production site has a problem, it immediately becomes a global issue.
Additionally, due to the complexity of the production process, high quality requirements and small margin for errors, injectable drugs may be more susceptible to manufacturing problems or quality issues than capsules or tablets. (5-7) Currently, drug shortages span across all major therapeutic areas, and medications it is imperative that they be cognizant of current shortages, and adequately respond to new shortages of transplant immunosuppressants.

